Rash News and Research

RSS

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

Celator Pharmaceuticals today announced positive clinical results in elderly patients with newly-diagnosed secondary acute myeloid leukemia (sAML) treated with CPX-351 Liposome Injection.

7 Jun 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.

6 Jun 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced efficacy and safety data from the BRIM3 trial, a large, randomized, multi-center Phase 3 clinical study of vemurafenib in patients with previously untreated metastatic melanoma with the BRAFV600 mutation.

6 Jun 2011

Ross River Fever vaccine trials begin

Australian researchers are working on a new vaccine that could protect against mosquito-borne Ross River Fever. They are conducting the world-first trial of the vaccine with positive results reported so far.

5 Jun 2011

Moisturisers, hair dyes cause serious adverse effects

Permanent hair dye gives the most serious adverse effects, yet there are also many reactions to facial and body moisturisers. This comes from the first report from the National Register of Adverse Effects from Cosmetic Products published by the Norwegian Institute of Public Health.

31 May 2011

YM announces updates on nimotuzumab clinical development program

YM BioSciences Inc., today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology.

31 May 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology annual meeting in Chicago that indicates combining its investigational therapy afatinib with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor.

26 May 2011

Largest number of measles cases in the US since 1996: Report

According to the latest report from the Centers for Disease Control and Prevention (CDC), the United States has had 118 measles cases so far this year, the most for this date since 1996, and close to 90% of them are linked to cases in other countries.

24 May 2011

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

The U.S. Food and Drug Administration today approved Incivek treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa and ribavirin.

24 May 2011

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Exelixis, Inc. today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

24 May 2011

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).

23 May 2011

Edurant receives FDA approval for treatment of HIV-1 infection

The U.S. Food and Drug Administration today approved Edurant (rilpivirine) in combination with other antiretroviral drugs for the treatment of HIV-1 infection in adults who have never taken HIV therapy (treatment-naive).

21 May 2011

Decision on destroying last of the stored small pox virus samples

Health experts from all over the world are to decide this week whether to hold on to the last remaining stockpiles of smallpox, one of the deadliest diseases in history – or to proceed with their destruction.

17 May 2011

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

InterMune, Inc. today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).

16 May 2011

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

New research shows that polymerase chain reaction testing for Borrelia burgdorferi DNA—the spirochetal bacteria transmitted by deer ticks—in joint fluid may confirm the diagnosis of Lyme arthritis, but is not a reliable indicator for active joint infection in patients whose arthritis persists after antibiotic therapy. Findings of this study are published in Arthritis & Rheumatism, a journal of the American College of Rheumatology.

13 May 2011

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that applications for market approval for vemurafenib for the treatment of metastatic melanoma have been submitted to the U.S. Food and Drug Administration and the European Medicines Agency.

11 May 2011

Scientists decipher genome of tropical marine organism

An international team of researchers led by scientists at Scripps Institution of Oceanography at UC San Diego has deciphered the genome of a tropical marine organism known to produce substances potentially useful against human diseases.

10 May 2011

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

On Thursday, the U.S. Food and Drug Administration approved Afinitor (everolimus) to treat patients with progressive neuroendocrine tumors located in the pancreas (PNET) that cannot be removed by surgery or that have spread to other parts of the body (metastatic).

7 May 2011

Filipino children with KD at greater risk for inflammation of heart blood vessels

While children of all ethnicities can contract Kawasaki disease (KD), a study led by researchers at the Kawasaki Disease Research Center at the University of California, San Diego and Rady Children's Hospital-San Diego finds that Filipino children with KD are at a higher risk for inflammation of the blood vessels of the heart than those of other Asian and non-Asian backgrounds.

7 May 2011

Rash News and Research

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Promising results from Exelixis' cabozantinib phase 2 trial against metastatic ovarian cancer

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Ross River Fever vaccine trials begin

Moisturisers, hair dyes cause serious adverse effects

YM announces updates on nimotuzumab clinical development program

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Largest number of measles cases in the US since 1996: Report

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Edurant receives FDA approval for treatment of HIV-1 infection

Decision on destroying last of the stored small pox virus samples

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

PCR testing for B. burgdorferi bacteria in joint fluid may confirm Lyme arthritis diagnosis

Plexxikon seeks vemurafenib marketing approval from FDA and EMA for melanoma treatment

Scientists decipher genome of tropical marine organism

FDA approves Afinitor for treatment of progressive neuroendocrine tumors in the pancreas

Filipino children with KD at greater risk for inflammation of heart blood vessels

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News